MDT-AP-1346
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 31.200000000000003
- os_event
- false
- age_years
- 10
- sex
- F
- new_clusters
- C2
- umap1_2d
- 2.850367347
- umap2_2d
- 1.985695005
- umap1_3d
- -0.060462863
- umap2_3d
- -2.868328307
- umap3_3d
- -2.675353751
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.340
- PANCREAS_BETA_CELLS+0.270
- OXIDATIVE_PHOSPHORYLATION+0.260
- G2M_CHECKPOINT+0.250
- DNA_REPAIR+0.240
- MYC_TARGETS_V2+0.240
- E2F_TARGETS+0.190
- KRAS_SIGNALING_DN+0.150
- WNT_BETA_CATENIN_SIGNALING+0.140
- FATTY_ACID_METABOLISM+0.070
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- INTERFERON_GAMMA_RESPONSE-0.390
- UV_RESPONSE_DN-0.390
- TNFA_SIGNALING_VIA_NFKB-0.380
- INFLAMMATORY_RESPONSE-0.370
- INTERFERON_ALPHA_RESPONSE-0.360
- ALLOGRAFT_REJECTION-0.310
- ANDROGEN_RESPONSE-0.300
- COMPLEMENT-0.290
- PROTEIN_SECRETION-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2286 | Med | Medulloblastoma | 0.886 |
| 2 | BS_JZRM1S3T | medulloblastoma | — | 0.886 |
| 3 | SRR15069607 | — | — | 0.880 |
| 4 | TCGA-OL-A5RZ-01A-11R-A28M-07 | — | C | 0.880 |
| 5 | MDT-AP-1339 | Med | Medulloblastoma | 0.879 |
| 6 | SRR25043617 | — | — | 0.879 |
| 7 | BS_HZRM07TW | medulloblastoma | — | 0.869 |
| 8 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.865 |
| 9 | BS_4D9DD103 | medulloblastoma | — | 0.865 |
| 10 | ERR2598250 | fetal | fetal | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |